|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, October 06, 2008 ) AUSTIN, Texas -- Munogenics, inc. in collaboration with a research team Led by Dr. Zheng Cui, MD/PhD, at Wake Forest University and will license US-based Munogenics Inc worldwide and today announced that they have entered a Global Marketing Agreement wih FranTech Switzerland, Global FranTech Group and FranTech's / FranMedics division a license agreement for Munogenics "GIFT" and "CKA" cell line technology testing to be licensed into 220 countries.
Under the terms of the FranTech / FranMedics Global Marketing Agreement, Munogenics will use Wake Forest University, Medical Center new cancer treatments technology for research in the field of adenovirus-based gene delivery for cancer treatment.
Munogenics has also obtained an option for a non-exclusive commercial license to use "GIFT" and "CKA" new cancer treatment cells process to manufacture and sell Munogenics future treatment products in the field of gene delivery for cancer treatment. Munogenics will receive upfront and annual payments for the research license marketed by FranTech / FranMedics Division into 220 countries.
If the Munogenics research license is converted into a commercial license, Munogenics will receive additional annual payments and royalties on future sales of 'GIFT" and "CKA"-derived products. Further financial details were not disclosed.
"This FranTech /FranMedics licensing into 220 countries represents an important building block in our Munogenics program to move Munogenics cancer treatments into clinical trials worldwide.
We perceive the Munogenics to be the best available for delivering the "GIFT" and "CKA" new cancer treatments ," said Dr.Beau Raines, President & CEO of Munogenics.
"We expect to sign the first Munogenics licencee's for "GIFT"
(GRANULOCYTE INFUSION THERAPY) treatment process, and the "CKA" (CANCER KILLING ACTIVITY) test license in 2009. Since that time "GIFT" and "CKA will become the new 'industry standard' in the area of adenovirus-based gene delivery.
Currently, no "GIFT" or "CKA"-based products are in clinical trials are in production," commented Phil Nadeau, Global FranTech Group's Chairman and CEO. "As worldwide interest in "GIFT" and "CKA" gene delivery expands, we believe new opportunities for future licensing agreements will further strengthen Munogenics's licensing value to this industry."
In collaboration with a research team led by Dr. Zheng Cui, MD/ PhD and Professor Mak Willingham, MD, at Wake Forest University School of Medicine, Medical Center, Munogenics plans to commercialize a new cancer treatment. termed the "GIFT" (Granulocyte InFusion Therapy) process, and "CKA" Cancer Killing Activity" test with the goal of eliminating various types of cancer in humans..
Munogenics, Inc. is committed to improving public health through the development of "GIFT" and "CKA" process and future development of advanced vaccines and antibodies that prevent or treat infectious diseases.
Munogenics, Inc will license development of vaccines and licenses its COMMERCIALIZING A NEW CANCER TREATMENT ("GIFT" and "CKA") process and production technology to Life Science companies in the pharmaceutical and biotechnology industry in 220 countries. The company's licensees include for its future cancer treatments "GIFT" and it's "CKA" CANCER vaccine, Munogenics "GIFT" and "CKA", licenses marketed through FranTech and FranMedics division, "A Worldwide Company" .
The Munogenics company has an alliance with "CKA" Biologics China to produce monoclonal antibodies and recombinant proteins. Munogenics has partnered with the US Wake Forest University for the development of an "GIFT" and "CKA" future vaccine. Munogenics is also be developing a human vaccine based on ("GIFT' and "CKA") studies. Munogenics, Inc. is headquartered in Austin, Texas, and is soon will be listed on the Euronext and NASDAQ stock exchanges (new ticker symbol may be MGIL).
For more information visit:
http://www.FranTechAsia.com
About Munogenics, Inc.
Munogenics Inc. develops,test, and licenses novel biological methods for treating and preventing malignant disease in humans. The company has a propriety revolutionary platform for cancer treatment that shows exceptional efficacy and minimal side effect in treating cancers.
Munogenics is developing a biotechnology company specialising in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.
Munogenics's will have a lead treatment process and product, the "GIFT"
(GRANULOCYTE INFUSION THERAPY) processes and the "CKA" (CANCER KILLING
ACTIVITY) test with the goal of eliminating various types of cancer in humans and producing a Munogenics cancer vaccine that will be an immunotherapy for many forms of cancer, including cancers of the lung, liver, kidney, head and neck, breast, prostate, and cervix, as well as colorectal cancer and melanoma.
These cancers are characterised by defects in the cellular, antigen presentation pathway, which results in the cancers becoming invisible to the immune system.
Munogenics future vaccine will increases the activity of the antigen presentation pathway thus providing sufficient information to the immune system to cause rejection and elimination of cancer from the body.
FranTech / FranMedics Divsion will Licence Munogenics, Inc., developments, test and licenses novel biologial methods for treating and preventing malignant diseases in humans. The Company has a worldwide proprietary revolutioary platform for cancer treatment that shows ecceptional efficacy and minimal side effects in treating cancers for worldwide licensing into 220 countries by FranTech / FranMedics division.
In collaboration with a world class research team led by Dr. Zheng Cui, MD/PhD, at Wake Forest University, Munogenics plans to comercialize a new cancer treatment, termed the "GIFT" (Granulocyte InFusion Therapy) prjocess, and the "CKA" (Cancer Killing Activity) test with the goal of eliminating various types of cancers in humans.
A UNQUE APPROACH - GIFT and CKA
The GIFT treatment process, discovered by Professor CUI, MD/PhD and Professor Mark Willingham, MD, has revealed during initial and subsequent testing that;
* certain humans posses a genetically defined and inheritable activity in their granulocytes to destroy a wide range of highly lethal cancers.
* this therapeutic activity can be transfused from cancer resistant donors to cancer-susceptible recipients for highly effective cancer treatment with minimal side effect.
Additionally, Munogencis also plans to licence and commercialize a proprietary human test measuring CKA to determine an individual's susceptibility, or resistance to various types of cancers so that the risk for cancer can be managed or prevented.
The CKA test will be used to identify potential donors fjor the GIFT cancers treatment process. Furthermore, the CKA test will measure granulocyte supplies in the following for humans:
*Selection for donors with high CKA (Cancer Therapy)
* Monitoring CKA in healthy population for cancer risk management (Prevention of Cancer)
* Monitoring CKA in cryo-stored cells (Aging Prevention)
CURRENT CANCER TREATMENTS
Current cancer treatments method revolve arjound the principal of using outside factors (surgery, radiation, cytotoxic chemotherapy) to seek out and destroy cancerous cells All of these treatments cause signifcant damage to healthy cells surrounding the cancer, causing dangerous side effects.
Conventional pathways from labortory discoveries to human trials using man-made cancer drug development usually require a lengthly process of testing efficacy and saftey and initial design and development.
The CKA-based approach of detecting and the GIFT therapeutic process for eliminating cancer relies on selecting specifically ready therapeutic reagents (human granulocytes) for direct use without any manipulation.
The collection and transfusion process for human granulocytes has previously been approved by the FDA for human clinical use for other clinical indications, such as infections associated with neutropenia.
The CKA testing approach has been previously validated using a sampling of over hundreds of human subjects.
A volunteer population eligible for granulocyte donation for testing the GIFT treatment process has been identified.
GIFT consists of 4 major novel components which distinguish it from other cancer immunotherapies:
* Collects donor cells from correct cancer-resistant humans based on screening for high CKA, but not from random donors.
* Collects and uses the specific types of donor cells which contain theh highest CKA and minimizes potential side-effects
* Collects the donor cells at the precisely most effective time, since CKA is influenced profoundly by seasonality.
* Collects sufficient number of granulocytes to achieve critical therapeutic doses
Munogenics Inc., is headquartered in Austin, Texas, USA and soon with licensed operations in worldwide in 220 markets.
For more information visit:
http://www.FranTechUSA.com
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements.
For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 18, 2003, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).
Distributed by FranTech USA on behalf of Global FranTech Group "A Worldwide Company"
Contact Information:
FranTech International Licensing Ltd.
2299 East Main Street, Suite 1000, Ventura, California 93001
David Baker, President
Tel : + 805-653-5264
Fax : + 805-643-4386
E-mail :
President@FranTechUSA.com
Copyright © 2008 Global FranTech Group. All rights reserved.
A FranTech Universal Business Media Company.
- FranMedics Division -Released October - 2008
www.FranTechWTC-3G.com
FranTech
David Baker
805-653-5264
President@FranTechUSA.com 
Source: EmailWire.com
|
|
|
|
